CD45RO-Positive Memory T-Cell Density in the Tumoral Core and Invasive Margin Predict Long-Term Survival in Esophageal Squamous Cell Carcinoma.

IF 3.4 2区 医学 Q2 ONCOLOGY Annals of Surgical Oncology Pub Date : 2025-03-01 Epub Date: 2024-12-05 DOI:10.1245/s10434-024-16530-z
Toshiki Noma, Tomoki Makino, Kenji Ohshima, Kotaro Yamashita, Takuro Saito, Koji Tanaka, Kazuyoshi Yamamoto, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Eiichi Morii, Hidetoshi Eguchi, Yuichiro Doki
{"title":"CD45RO-Positive Memory T-Cell Density in the Tumoral Core and Invasive Margin Predict Long-Term Survival in Esophageal Squamous Cell Carcinoma.","authors":"Toshiki Noma, Tomoki Makino, Kenji Ohshima, Kotaro Yamashita, Takuro Saito, Koji Tanaka, Kazuyoshi Yamamoto, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Eiichi Morii, Hidetoshi Eguchi, Yuichiro Doki","doi":"10.1245/s10434-024-16530-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The association between tumor-infiltrating lymphocytes and tumor immunity has long been recognized. Among T-cell types, CD45RO-positive memory T cells (CD45RO<sup>+</sup>) are reported to correlate with survival in several cancer types, but clinical evidence is lacking in esophageal squamous cell carcinoma (ESCC).</p><p><strong>Methods: </strong>In surgical specimens from 162 preoperatively untreated patients, immunohistochemistry for CD45RO was performed to evaluate the density of CD45RO<sup>+</sup> in the tumor core (CT) and invasive margin (IM) using an auto-count method. Patients were classified into high- versus low-CD45RO<sup>+</sup> groups based on CD45RO<sup>+</sup> density in CT and IM separately and combined. The relationship between CD45RO<sup>+</sup> density and clinicopathological factors, including prognosis, was evaluated.</p><p><strong>Results: </strong>Average CD45RO<sup>+</sup> density was 133/mm<sup>2</sup> in CT and 372/mm<sup>2</sup> in IM. No significant differences in clinicopathological factors according to high- versus low-CD45RO<sup>+</sup> scores were identified. Using CT scores, the CD45RO<sup>+</sup>-high group had a better 5-year overall survival (OS) rate (77.2% vs. 54.7% CD45RO<sup>+</sup>-low, P = 0.0433), but OS rates did not differ statistically between the two groups by IM scores (75.7% vs. 50.3%, P = 0.0576). Using immunohistochemical scores for CT+IM, the survival difference was significant, with a 5-year OS rate of 73.7% for the CD45RO<sup>+</sup>-high group versus 46.3% for the CD45RO<sup>+</sup>-low group (P = 0.0141). Multivariate analysis identified CD45RO<sup>+</sup> CT+IM density as an independent prognostic variable in OS (hazard ratio 2.27, 95% confidence interval 1.43-3.62, P = 0.0006).</p><p><strong>Conclusions: </strong>Density of CD45RO<sup>+</sup> expression in the CT and IM might be a predictor of long-term survival in ESCC.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"1953-1962"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811247/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1245/s10434-024-16530-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The association between tumor-infiltrating lymphocytes and tumor immunity has long been recognized. Among T-cell types, CD45RO-positive memory T cells (CD45RO+) are reported to correlate with survival in several cancer types, but clinical evidence is lacking in esophageal squamous cell carcinoma (ESCC).

Methods: In surgical specimens from 162 preoperatively untreated patients, immunohistochemistry for CD45RO was performed to evaluate the density of CD45RO+ in the tumor core (CT) and invasive margin (IM) using an auto-count method. Patients were classified into high- versus low-CD45RO+ groups based on CD45RO+ density in CT and IM separately and combined. The relationship between CD45RO+ density and clinicopathological factors, including prognosis, was evaluated.

Results: Average CD45RO+ density was 133/mm2 in CT and 372/mm2 in IM. No significant differences in clinicopathological factors according to high- versus low-CD45RO+ scores were identified. Using CT scores, the CD45RO+-high group had a better 5-year overall survival (OS) rate (77.2% vs. 54.7% CD45RO+-low, P = 0.0433), but OS rates did not differ statistically between the two groups by IM scores (75.7% vs. 50.3%, P = 0.0576). Using immunohistochemical scores for CT+IM, the survival difference was significant, with a 5-year OS rate of 73.7% for the CD45RO+-high group versus 46.3% for the CD45RO+-low group (P = 0.0141). Multivariate analysis identified CD45RO+ CT+IM density as an independent prognostic variable in OS (hazard ratio 2.27, 95% confidence interval 1.43-3.62, P = 0.0006).

Conclusions: Density of CD45RO+ expression in the CT and IM might be a predictor of long-term survival in ESCC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
cd45ro阳性记忆t细胞密度在食管鳞状细胞癌的肿瘤核心和浸润边缘预测长期生存。
背景:肿瘤浸润淋巴细胞与肿瘤免疫之间的关系早已被认识到。在T细胞类型中,CD45RO阳性记忆T细胞(CD45RO+)被报道与几种癌症类型的生存相关,但在食管鳞状细胞癌(ESCC)中缺乏临床证据。方法:对162例术前未治疗患者的手术标本进行CD45RO免疫组化,采用自动计数法评估肿瘤核心(CT)和浸润边缘(IM)的CD45RO+密度。根据CT和IM中的CD45RO+密度分别和联合将患者分为高CD45RO+组和低CD45RO+组。评估CD45RO+浓度与临床病理因素(包括预后)的关系。结果:CD45RO+ CT平均密度133/mm2, IM平均密度372/mm2。根据高和低cd45ro +评分,临床病理因素没有明显差异。从CT评分来看,CD45RO+高组的5年总生存率(OS)更高(77.2% vs. 54.7%, P = 0.0433),而IM评分两组的OS无统计学差异(75.7% vs. 50.3%, P = 0.0576)。使用CT+IM的免疫组织化学评分,生存差异具有统计学意义,CD45RO+高组的5年OS率为73.7%,而CD45RO+低组为46.3% (P = 0.0141)。多因素分析发现CD45RO+ CT+IM密度是OS的独立预后变量(风险比2.27,95%可信区间1.43 ~ 3.62,P = 0.0006)。结论:CD45RO+在CT和IM中的表达密度可能是ESCC患者长期生存的一个预测指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.90
自引率
10.80%
发文量
1698
审稿时长
2.8 months
期刊介绍: The Annals of Surgical Oncology is the official journal of The Society of Surgical Oncology and is published for the Society by Springer. The Annals publishes original and educational manuscripts about oncology for surgeons from all specialities in academic and community settings.
期刊最新文献
ASO Visual Abstract: Living Flat-Stories from Women of Color After Mastectomy. ASO Visual Abstract: Comparison of Ampullary and Pancreatic Adenocarcinomas-Smaller Invasion, Common Adenomatous Components, Resectability, and Histology are Factors for Improved Survival for Patients with Ampullary Adenocarcinoma. ASO Visual Abstract: The Predictive Factors of Combined Implant Application for Breast Cancer Patients Receiving Immediate Breast Reconstruction with a Pedicled Omental Flap. ASO Visual Abstract: The Impact of Radioactive Iodine on Disease-Specific Survival in Low-to-Intermediate Risk N1b Papillary Thyroid Carcinoma. ASO Visual Abstract: An Organoid Model for the Therapeutic Effect of Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1